Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

You may also be interested in...



Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.

Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.

Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,

From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel